Form 4: 89bio Director's Options Disposed in Roche Merger

Lota S. Zoth, a director at 89bio, Inc., disposed of stock options as part of the company's acquisition by Roche Holdings, Inc. on October 30, 2025.

Summary

• 89bio, Inc. was acquired by Roche Holdings, Inc. through its subsidiary Bluefin Merger Subsidiary, Inc., with the merger effective on October 30, 2025.
• The acquisition involved a tender offer for all outstanding shares of 89bio common stock at an offer price of $14.50 per share in cash (Closing Amount) plus one non-tradeable contingent value right (CVR).
• Each CVR represents the right to receive contingent payments of up to an aggregate amount of $6.00 per share upon the achievement of specified milestones.
• Lota S. Zoth, a director of 89bio, disposed of a total of 186,450 stock options as a result of the merger.
• All outstanding options became fully vested and exercisable immediately prior to the merger's effective time.
• Options with an exercise price below the $14.50 Closing Amount were converted into cash equal to the difference between the Closing Amount and the exercise price, plus one CVR per share.
• Options with an exercise price between $14.50 and $20.50 (Out of the Money Options) were converted into CVRs, with cash payments contingent on milestone achievements.
• Options with an exercise price equal to or greater than $20.50 were cancelled without any payment (cash or CVR).
• Specifically, 32,500 options with exercise prices of $24.05 and $24.16 were cancelled without payment.
• 126,550 options with exercise prices of $2.64, $9.98, and $9.60 were converted into cash payments totaling approximately $776,887 and 126,550 CVRs.
• 27,400 options with an exercise price of $14.70 were converted into 27,400 CVRs, with cash payments contingent on milestones.

Sentiment

Score: 7

Explanation: The merger successfully closed, providing immediate cash and potential future value for most option holders, though some high-strike options were cancelled without payment. The CVRs introduce an element of future uncertainty.

Positives

• The successful completion of the merger provides immediate liquidity for 89bio shareholders and option holders with in-the-money options.
• Option holders with exercise prices below $14.50 received cash payments totaling approximately $776,887 for Lota S. Zoth's holdings, in addition to CVRs.
• The inclusion of Contingent Value Rights (CVRs) offers potential for additional future payments of up to $6.00 per share if specified milestones are met.

Negatives

• Options with an exercise price equal to or greater than $20.50 were cancelled without any payment, resulting in a loss of potential value for those specific holdings (32,500 options for Lota S. Zoth).
• Options with exercise prices between $14.50 and $20.50 only received CVRs initially, with cash payments contingent on future milestone achievements, introducing uncertainty and delayed realization of value.
• 89bio, Inc. ceases to be an independent publicly traded company, becoming a wholly-owned subsidiary of Roche Holdings, Inc.

Risks

• The value of the Contingent Value Rights (CVRs) is uncertain and dependent on the achievement of specified milestones, which may not occur.
• CVRs are non-tradeable, limiting liquidity and the ability to realize their value before milestone achievement.
• Option holders with 'Out of the Money Options' (exercise price between $14.50 and $20.50) bear the risk that milestones may not be met, potentially resulting in no additional cash payment beyond the CVRs.

Future Outlook

89bio, Inc. is now a wholly-owned subsidiary of Roche Holdings, Inc., and its future operations and strategic direction will be integrated into Roche's broader corporate strategy. The future value for former 89bio shareholders and option holders holding CVRs depends on the achievement of specified milestones for contingent payments.

Industry Context

This acquisition reflects a broader trend in the biotechnology and pharmaceutical industry where larger, established pharmaceutical companies like Roche acquire smaller biotechs to expand their pipeline, gain access to innovative therapies, and consolidate market position. Such mergers often provide a significant premium for the acquired company's shareholders while integrating promising assets into a larger R&D and commercialization framework.

Corporate Governance

Stakeholder Impact

• Shareholders: Received $14.50 cash per share plus one non-tradeable CVR, providing immediate value and potential future upside.
• Option Holders (like Lota S. Zoth): In-the-money options converted to cash and CVRs; out-of-the-money options converted to CVRs with contingent cash; deeply out-of-the-money options cancelled without payment.
• Employees: 89bio employees are now part of Roche Holdings, Inc., subject to Roche's employment policies and organizational structure.
• 89bio as an Entity: Ceases to exist as an independent public company, becoming a subsidiary of a major pharmaceutical firm.

Next Steps

• Integration of 89bio's operations and assets into Roche Holdings, Inc.
• Monitoring the achievement of specified milestones for the contingent payments associated with the CVRs.

Key Dates

Keywords

89bio, ETNB, Roche Holdings, Merger, Acquisition, Tender Offer, Form 4, Insider Transaction, Stock Options, Contingent Value Rights, CVR, Lota S. Zoth, Biotechnology, Pharmaceuticals